Drug Discovery Featured Articles & Applications

  1. Antibiotic-Resistant STIs: Men's Health Is Entering A New Era Of Therapeutic Risk 4/20/2026

    What was once a reliably treatable infection is increasingly defined by resistance patterns that limit therapeutic options and complicate management.

  2. If AI Can't Read Your Science, Investors Won't Either 4/17/2026

    As investors deploy AI to screen thousands of deals at once, life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.

  3. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  4. There's A Gap In Brain Tumor Research — Here's How We Fix It 4/9/2026

    Brain tumors are some of the most biologically complex and least improved indications. Biochemistry researcher and scientist Catherine Bladen, Ph.D., argues sustained focus is a key to driving real-world progress.

  5. Lessons Learned While Taking Glioblastoma Drug From Bench To Clinic 4/9/2026

    MimiVax CEO Mike Ciesielski recounts the company's transition from academia to industry, hitting on topics like vendor partnerships, FDA conversations, and manufacturer selection. 

  6. Next‑Generation Omics: Latest Insights From A Growing Field 4/8/2026

    Experts share their latest discovery and translational research using multi-omics technologies at the NextGen Omics Spatial & Data conference in Boston.

  7. AI Drug Discovery Is Revealing The Preclinical Bottleneck 4/8/2026

    For the generative AI revolution in drug discovery to deliver on its promise, the industry needs more than better molecules, it needs a better pipeline architecture.

  8. Beyond Biologics: A Biophysical Approach To Crohn's Disease 4/2/2026

    Research into a nano-amorphous approach suggests a new breakthrough in Crohn’s management may come from a shift toward modulating the biophysical environment of the gut.

  9. Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics? 4/1/2026

    Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.

  10. The Missing Data Set In Drug Discovery: Patient Experience As Decision Data 3/30/2026

    Drug discovery has become highly effective at capturing molecular detail, yet the experience of disease remains difficult to incorporate into early scientific decisions.